Management of treatment-resistant depression

Psychiatric Clinics of North America

Volumn 35, Issue 1, 2012, Pages 249-265

  Keitner, Gabor I ^a,b,c   Mansfield, Abigail K ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MIRIAM HOSPITAL   (United States)

Author keywords

Depression; Disease management; Treatment; Treatment resistance

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ARIPIPRAZOLE; BUSPIRONE; FOLIC ACID; INOSITOL; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MELATONIN; MIRTAZAPINE; MODAFINIL; OLANZAPINE; OMEGA 3 FATTY ACID; PINDOLOL; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RILUZOLE; RISPERIDONE; ROPINIROLE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; COUGHING; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; ELECTROCONVULSIVE THERAPY; FAMILY THERAPY; HOARSENESS; HUMAN; MELANCHOLIA; MILIEU THERAPY; NECK PAIN; ONSET AGE; PANIC; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSURGERY; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SELF CARE; SOCIAL PHOBIA; SOCIAL PSYCHOLOGY; SUICIDE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; VAGUS NERVE STIMULATION;

ANTIDEPRESSIVE AGENTS; BORDERLINE PERSONALITY DISORDER; COMORBIDITY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED PRACTICE; FAMILY THERAPY; HUMANS; META-ANALYSIS AS TOPIC; PSYCHOTHERAPY; RECURRENCE; REVIEW LITERATURE AS TOPIC; RISK FACTORS; TREATMENT FAILURE;

EID: 84857377072     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2011.11.004     Document Type: Review

References (102)

1. Rush A.J., Thase M., Dube S. Research issues in study of difficult-to-treat depression. Biol Psychiatry 2003, 53:743-753.
2. Sackeim H.A. The definition and meaning of treatment resistant depression. J Clin Psychiatry 2001, 62(16):10-17.
3. Crown W.H., Finkelstein S., Berndt E.R., et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002, 63(11):963-971.
4. Berlim M.T., Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)?. A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007, 17(11):696-707.
5. Thase M., Rush A.J. What at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(Suppl 13):23-29.
6. Souery D., Amsterdam J., de Montigny C., et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999, 9(1-2):83-91.
7. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53:649-659.
8. Fekadu A., Wooderson S., Donaldson C., et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009, 70(2):177-184.
9. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007, 52(1):46-54.
10. Lopez A.D., Mathers C.D., Ezzari M., et al. Global and regional burden of disease risk factors: systematic analysis of population health data. Lancet 2001, 367:1747-1757.
11. Greden J.F., Riba M.B., McInnis M.G. Treatment resistant depression: a roadmap for effective care 2011, American Psychiatric Publishing, Washington, DC.
12. Greden J.F. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001, 62(Suppl 16):26-31.
13. Dunner D.L., Rush A.J., Russell J.M., et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006, 67(5):688-695.
14. Fekadu A., Wooderson S.C., Markopoulo K., et al. What happens to patients with treatment-resistant depression?. A systematic review of medium to long term outcome studies. J Affect Disord 2009, 116(1-2):4-11.
15. Gaynes B.N., Warden D., Trivedi M.H., et al. What did STAR*D teach us?. Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009, 60(11):1439-1445.
16. Wooderson S.C., Juruena M.F., Fekadu A., et al. Prospective evaluation of specialist inpatient treatment for refractory affective disorders. J Affect Disord 2011, 131(1-3):92-103.
17. Fava G.A., Offidani E. The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(7):1593-1602.
18. Whitaker R. Anatomy of an epidemic 2010, Crown, New York.
19. Andrews P.W., Kornstein S.G., Halberstadt L.J., et al. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011, 2(Article 159):1-24.
20. Young A.M., Goudie A.J. Adapative processes regulating tolerance to behavioral effects of drugs. Psychopharmacology 1995, 733-742. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
21. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996, 153(2):151-162.
22. Souery D., Oswald P., Massat I., et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007, 68(7):1062-1070.
23. Gorwood P., Rouillon F., Even C., et al. Treatment response in major depression: effects of personality dysfunction and prior depression. Br J Psychiatry 2010, 196(2):139-142.
24. Holzel L., Harter M., Reese C., et al. Risk factors for chronic depression-a systematic review. J Affect Disord 2011, 129(1-3):1-13.
25. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Pscyhiatry 2006, 163(11):1905-1917.
26. Kennedy N., Paykel E.S. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004, 80(2-3):135-144.
27. Stahl S.M. Why settle for silver, when you can go for gold?. Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry 1999, 60(4):213-214.
28. Ferrier I.N. Treatment of major depression: is improvement enough?. J Clin Psychiatry 1999, 60(Suppl 6):10-14.
29. McIntyre R.S., O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004, 49(3 Suppl 1):10S-16S.
30. Keitner G.I., Ryan C.E., Solomon D.A. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006, 67:1412-1421.
31. Fava G.A. Can long-term treatment with antidepressant drugs worsen the course of depression?. J Clin Psychiatry 2003, 64(2):123-133.
32. Joyce P.R., Mulder R.T., Cloninger C.R. Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord 1994, 30(1):35-46.
33. Joyce P.R., Paykel E.S. Predictors of drug response in depression. Arch Gen Psychiatry 1989, 46(1):89-99.
34. Scott J., Williams J.M., Brittlebank A., et al. The relationship between premorbid neuroticism, cognitive dysfunction and persistence of depression: a 1-year follow-up. J Affect Disord 1995, 33(3):167-172.
35. Steunenberg B., Beekman A.T.F., Deeg D.J.H., et al. Personality predicts recurrence of late-life depression. J Affect Disord 2010, 123:164-172.
36. Reynaert C., Janne P., Vause M., et al. Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome. Psychopharmacology [Berl] 1995, 119(4):449-454.
37. Sullivan M.D., Katon W.J., Russo J.E., et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract 2003, 16(1):22-31.
38. Sirey J.A., Bruce M.L., Alexopoulos G.S., et al. Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv 2001, 52(12):1615-1620.
39. Mintz D.L., Belnap B.A. What is psychodynamic psychopharmacology?. An approach to pharmacological treatment resistance. Treatment resistance and patient authority: an Austen Riggs reader 2011, 42-65. Norton, New York. E.M. Plakun (Ed.).
40. Bagby R.M., Ryder A.G., Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002, 27(4):250-257.
41. Ezquiaga E., Garcia A., Bravo F., et al. Factors associated with outcome in major depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol 1998, 33(11):552-557.
42. Keitner G.I., Heru A.M., Glick I.D. Clinical manual of couples and family therapy 2010, American Psychiatric Publishing, Washington, DC.
43. Shelton R.C., Osuntokun O., Heinloth A.N., et al. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24(2):131-161.
44. Lam R.W., Kennedy S.H., Grigoriadis S., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117(Suppl 1):S26-S43.
45. Thakur M., Grossman I., McCrory D.C., et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007, 9(12):826-835.
46. Souery D., Serretti A., Calati R., et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 2011, 31(4):512-516.
47. Crossley N.A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007, 68(6):935-940.
48. Nierenberg A., Fava M., Trivedi M.H., et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D Report. Am J Psychiatry 2006, 163:1519-1530.
49. Guzzetta F., Tondo L., Centorrino F., et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007, 68(3):380-383.
50. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166(9):980-991.
51. Cooper-Kazaz R., Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008, 11(5):685-699.
52. Folkerts H.W., Michael N., Tolle R., et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression-a randomized study. Acta Psychiatr Scand 1997, 96(5):334-342.
53. Devanand D.P., Sackeim H.A., Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatr Clin North Am 1991, 14(4):905-923.
54. Eschweiler G.W., Vonthein R., Bode R., et al. Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression. J Affect Disord 2007, 101(1-3):149-157.
55. Rush A.J., Marangell L.B., Sackeim H.A., et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58(5):347-354.
56. Rush A.J., Sackeim H.A., Marangell L.B., et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005, 58(5):355-363.
57. Kennedy S.H., Giacobbe P. Treatment resistant depression-advances in somatic therapies. Ann Clin Psychiatry 2007, 19(4):279-287.
58. Taylor S.F., Goldman M., Maixner D.F., et al. Device-related neuromodulation in treatment resistant depression. Treatment resistant depression: a roadmap for effective care 2011, 213-235. American Psychiatric Publishing, Washington, DC. J.F. Greden, M.B. Riba, M.G. McInnis (Eds.).
59. Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med 2007, 356(16):1604-1607.
60. Sackeim H.A., Rush A.J., George M.S., et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001, 25(5):713-728.
61. George M.S., Rush A.J., Marangell L.B., et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005, 58(5):364-373.
62. Grunhaus L., Schreiber S., Dolberg O.T., et al. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003, 53(4):324-331.
63. Avery D.H., Holtzheimer P.E., Fawaz W., et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006, 59(2):187-194.
64. Rossini D., Lucca A., Zanardi R., et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005, 137(1-2):1-10.
65. Loo C., Mitchell P., Sachdev P., et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999, 156(6):946-948.
66. Boutros N.N., Gueorguieva R., Hoffman R.E., et al. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Res 2002, 113(3):245-254.
67. Poulet E., Brunelin J., Boeuve C., et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 2004, 19(6):382-383.
68. Holtzheimer P.E., Avery D., Schlaepfer T.E. Antidepressant effects of repetitive transcranial magnetic stimulation. Br J Psychiatry 2004, 184:541-542.
69. Fitzgerald P.B., Benitez J., de Castella A., et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006, 163(1):88-94.
70. Wassermann E.M. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998, 108(1):1-16.
71. Sachdev P.S., Sachdev J. Long-term outcome of neurosurgery for the treatment of resistant depression. J Neuropsychiatry Clin Neurosci 2005, 17(4):478-485.
72. Mayberg H.S., Lozano A.M., Voon V., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45(5):651-660.
73. Trivedi R.B., Nieuwsma J.A., Williams J.W. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2010, 26(6):643-650.
74. Thase M.E., Friedman E.S., Biggs M.M., et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007, 164(5):739-752.
75. Scott J., Teasdale J.D., Paykel E.S., et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry 2000, 177:440-446.
76. Harley R., Sprich S., Safren S., et al. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. J Nerv Ment Dis 2008, 196(2):136-143.
77. Kennedy S.H., Segal Z.V., Cohen N.L., et al. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry 2003, 64(4):439-444.
78. Blackburn I.M., Moore R.G. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997, 171:328-334.
79. Wiles N.J., Hollinghurst S., Mason V. A randomized controlled trial of cognitive behavioural therapy as an adjunct to pharmacotherapy in primary care based patients with treatment resistant depression: a pilot study. Behav Cogn Psychotherapy 2008, 36:21-33.
80. Keitner G.I., Miller I.W., Epstein N.B., et al. Family functioning and the course of major depression. Compr Psychiatry 1987, 28(1):54-64.
81. Keitner G.I., Miller I.W. Family functioning and major depression: an overview. Am J Psychiatry 1990, 147(9):1128-1137.
82. Keitner G.I., Ryan C.E., Miller I.W., et al. Role of the family in recovery and major depression. Am J Psychiatry 1995, 152(7):1002-1008.
83. Clarkin J.F., Glick I.D., Haas G.L., et al. A randomized clinical trial of inpatient family intervention. J Affect Dis 1990, 18:17-28.
84. Jacobson N.S., Dobson K., Fruzzetti A.E., et al. Martial therapy as a treatment for depression. J Consult Clin Psychol 1991, 59(4):547-557.
85. Beach S., O'Leary D. The treatment of depression occurring in the context of marital discord. Behav Ther 1986, 17:43-49.
86. Leff J., Vearnals S., Wolff G., et al. The London Depression Intervention Trial. Randomized controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. Br J Psychiatry 2000, 177:95-100.
87. Keitner G.I., Archambault R., Ryan C.E., et al. Family therapy and chronic depression. J Clin Pract 2003, 59(8):873-884.
88. Miller I.W., Keitner G.I., Ryan C.E., et al. Treatment matching in the post hospital care of depressed patients. Am J Psychiatry 2005, 162:2131-2138.
89. Hartmann M., Bazner E., Wild B., et al. Effects of interventions involving the family in the treatment of adult patients with chronic physical diseases: a meta-analysis. Psychother Psychosom 2010, 79(3):136-148.
90. Andrews G. Should depression be managed as a chronic disease?. BMJ 2001, 322(7283):419-421.
91. Katon W., Guico-Pabia C. Improving quality of depression care using organized systems of care: a review of the literature. Prim Care Comp CNS Disord 2011, 13(1). pil: PCC 10x0109blu.
92. Ofman J.J., Badamgarav E., Henning J.M., et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases?. A systematic review. Am J Med 2004, 117(3):182-192.
93. Neumeyer-Gromen A., Lampert T., Stark K., et al. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care 2004, 42(12):1211-1221.
94. Gilbody S., Bower P., Fletcher J., et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006, 166(21):2314-2321.
95. Williams J.W., Gerrity M., Holsinger T., et al. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psych 2007, 29:91-116.
96. Ryan C.E., Keitner G.I., Bishop S. An adjunctive management of depression program for difficult-to-treat depressed patients and their families. Depress Anxiety 2009, 27(1):27-34.
97. Yeung A., Feldman G., Fava M. Self-management of depression: a manual for mental health and primary care professionals 2010, Cambridge University Press, New York.
98. Lam R.W., Fiteau M., Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord 2011, 132:S9-S13.
99. Patten S., Grigoriadis S., Beaulieu S. Clinical effectiveness, construct and assessment. J Affect Disord 2011, 132:S3-S8.
100. Zimmerman M., Galione J.N., Attiullah N., et al. Depressed patients' perspectives of 2 measures of outcome: the Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ). Ann Clin Psychiatry 2011, 23(3):208-212.
101. Harris A., Cronkite R., Moos R. Physical activity, exercise coping, and depression in a 10-year cohort study of depressed patients. J Affect Disord 2006, 93:79-85.
102. Trivedi M.H., Greer T.L., Church T.S., et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 2011, 72(5):677-684.